Postępy w leczeniu drobnokomórkowego raka płuca

© Borgis - Nowa Medycyna 5-6/2001

Jacek Jassem

Summary
SCLC represents 20% of all lung cancer cases. The cornerstone of its management was the introduction of chemotherapy in the early 1970s. With currently used regimens response can be achieved in about 80% of patients but its attaining is difficult. Recently a number of new chemotherapeutic and biological agents have been tested in SCLC, yet their role remains to be established. In limited SCLC a progress has been achieved with the routine introduction of thoracic and cranial radiotherapy. Despite these advances, cure is still a rare endpoint in SCLC. Clearly, improved systemic therapies are desperately needed if more patients with this malignancy are to enjoy a prospect of long-term survival.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.